Reported Saturday, Johnson & Johnson Reports 57% Of Psoriatic Arthritis Patients With Qualifying Skin Involvement On ICOTYDE Achieved Clear Or Almost Clear Skin Versus 14% On Placebo, Alongside 58% ACR20 Response At Week 16
Benzinga Newsdesk 1 day ago
News
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at
- Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16
- ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill